Incyte Corp. (INCY): price, analyst ratings, earnings and fundamentals
Updated 15 October 2026, 21:45 ET
Incyte Corp. (INCY) closed at $113.27 on 15 October 2026, up 1.5%. The stock is down 9.2% over one month and up 31.8% over one year. It trades 14.6% below its 52-week high of $132.60. Analysts recorded 22 actions in the last 90 days; the median price target of $130 is 14.8% above the last close. The company last reported on 28 July 2026 for Q2 2026: EPS of $3.09 against an estimate of $1.84, a beat of 67.9%, on revenue of $1.7 billion.
Price and performance
Performance figures use dividend and split adjusted closes over trading sessions, so a one-year move compares the last close with the close 252 sessions earlier. The 52-week range uses the adjusted daily highs and lows of the same window. Read the guide: Momentum, trend and technical indicators.
The live chart with technical indicators is in the app: open INCY in FundSpec.
Analyst ratings
Over the last 90 days FundSpec recorded 22 analyst actions on INCY from 14 firms: 21 maintained or reiterated a view and 1 initiation. Price targets were 16 raised. The most recent targets from 17 firms range from $90 to $157, with a median of $130, 14.8% above the last close.
| Date | Firm | Action | Price target |
|---|---|---|---|
| 14 Oct 2026 | Truist Securities | Maintains Hold | $105.00 to $115.00 |
| 13 Oct 2026 | HC Wainwright & Co. | Reiterates Buy | $152.00 |
| 8 Oct 2026 | RBC Capital | Maintains Sector Perform | $109.00 to $114.00 |
| 5 Oct 2026 | Stifel | Maintains Buy | $145.00 to $157.00 |
| 1 Oct 2026 | Wells Fargo | Maintains Equal-Weight | $116.00 to $128.00 |
| 28 Sep 2026 | JP Morgan | Maintains Neutral | $120.00 to $123.00 |
| 28 Sep 2026 | HC Wainwright & Co. | Maintains Buy | $150.00 to $152.00 |
| 22 Sep 2026 | RBC Capital | Reiterates Sector Perform | $109.00 |
| 20 Aug 2026 | Canaccord Genuity | Initiates Coverage On Buy | $152.00 |
| 20 Aug 2026 | HC Wainwright & Co. | Reiterates Buy | $150.00 |
A price target is one firm's twelve-month view, and the median across firms is a steadier reading than any single call. Upgrades and downgrades matter more when they change a rating, not only a target. Read the guide: What analyst ratings and price targets actually tell you.
Every action with the firm's history is in Analyst Ratings.
Earnings
The next report is scheduled for 29 October 2026 before the open for Q3 2026, with EPS expected at -$3.80 on revenue of $1.5 billion. Incyte Corp. beat the EPS estimate in 5 of its last 8 reported quarters.
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| Q2 2026 | 28 Jul 2026 | $1.84 | $3.09 | +67.93% | $1.7B |
| Q1 2026 | 28 Apr 2026 | $1.31 | $1.81 | +38.17% | $1.3B |
| Q4 2025 | 10 Feb 2026 | $1.83 | $1.80 | -1.64% | $1.5B |
| Q3 2025 | 28 Oct 2025 | $1.53 | $2.26 | +47.71% | $1.4B |
| Q2 2025 | 29 Jul 2025 | $1.34 | $1.57 | +17.16% | $1.2B |
| Q1 2025 | 29 Apr 2025 | $1.03 | $1.16 | +12.62% | $1.1B |
| Q4 2024 | 10 Feb 2025 | $1.55 | $1.43 | -7.74% | $1.2B |
| Q3 2024 | 29 Oct 2024 | $1.09 | $1.07 | -1.83% | $1.1B |
An earnings surprise is the reported EPS against the consensus estimate on the day. The price reaction depends as much on guidance and on what was already priced in as on the surprise itself. Read the guide: Earnings season: estimates, surprises and price reaction.
Estimates, confirmed dates and alerts for every company are in Earnings.
Fundamentals
For the period ended 31 March 2026, Incyte Corp. reported revenue of $1.3 billion and net income of $303.3 million. On a trailing twelve month basis the company shows revenue growth of 21.48%, a gross margin of 92.47%, an operating margin of 30.05% and a return on equity of 30.82%.
Income statement
| Line | Amount |
|---|---|
| Revenue | $1,272,676,000 |
| Gross Profit | $1,168,153,000 |
| Research and Development | $515,903,000 |
| Selling, General & Administrative Expenses | $328,087,000 |
| Depreciation & Amortization | $23,802,000 |
| Total Operating Expenses | $971,559,000 |
| Operating Profit | $301,117,000 |
| Interest Expense | $569,000 |
| Pre-tax Income | $343,600,000 |
| Income Tax Expense | $40,270,000 |
| Net Income | $303,330,000 |
Cash flow
| Line | Amount |
|---|---|
| Cash from Operating Activities | $369,351,000 |
| Stock-based Compensation | $64,126,000 |
| Cash from Investing Activities | -$88,203,000 |
| Cash from Financing Activities | $84,822,000 |
Assets
| Line | Amount |
|---|---|
| Cash & Cash Equivalents | $3,461,114,000 |
| Prepaid Expenses | $301,312,000 |
| Inventory | $115,624,000 |
| Total Current Assets | $5,484,260,000 |
| Plant, Property & Equipment, Net | $720,169,000 |
| Goodwill Intangible Assets, Net | $133,000,000 |
| Deferred Tax Asset | $528,172,000 |
| Other Long-term Assets | $24,492,000 |
| Total Assets | $7,339,113,000 |
Liabilities and equity
| Line | Amount |
|---|---|
| Accounts Payable & Accrued Expenses | $228,624,000 |
| Total Short-term Debt | $4,413,000 |
| Operating Lease Liabilities, Current | $5,603,000 |
| Income Taxes Payable | $5,934,000 |
| Other Current Liabilities | $78,444,000 |
| Total Current Liabilities | $1,489,649,000 |
| Operating Lease Liabilities, Long-term | $14,508,000 |
| Finance Lease Liabilities | $33,827,000 |
| Other Liabilities | $126,587,000 |
| Total Liabilities | $1,716,266,000 |
| Common Stock | $200,000 |
| Retained Earnings | $517,099,000 |
| Other Accumulated Comprehensive Income | $22,314,000 |
| Total Stockholders Equity | $5,622,847,000 |
| Total Liability & Stockholders Equity | $7,339,113,000 |
Figures as filed with the SEC for the period ended 31 March 2026, in US dollars.
FundSpec fundamental metrics
Each metric is computed from the company's filings and ranked against every company FundSpec covers; the percentile is the share of covered companies with a lower value.
Liquidity
| Metric | Value | Percentile | What it measures |
|---|---|---|---|
| Cash Ratio | 2.32 | 85th | Calculated as the ratio of Cash and cash equivalents / Current liabilities. This metric calculates the company's ability to repay its short-term debt |
| Current Ratio | 3.68 | 83rd | Calculated as the ratio of Current Assets / Current Liabilities. The higher the current ratio, the more capable the company is of paying its obligations |
Leverage
| Metric | Value | Percentile | What it measures |
|---|---|---|---|
| Debt/Assets | 0.00 | 40th | Calculated as the ratio of Short-Term Debt + Long-Term Debt / Total Assets. The higher the ratio, the higher the degree of leverage, and consequently, financial risk |
| Debt/Equity | 0.01 | 32nd | Calculated as the ratio of Total Liabilities / Shareholders' Equity. The ratio indicates how much debt a company is using to finance its assets relative to the amount of value represented in shareholders’ equity |
| Degree of Combined Leverage | 18.65 | 93rd | This ratio summarizes the combined effect that the degree of operating leverage (DOL) and the degree of financial leverage have on earnings per share (EPS), given a particular change in sales |
| Degree of Financial Leverage | 1.00 | 54th | Calculated as the ratio of Percentage change in EPS / Percentage change in EBIT. A higher degree of financial leverage means that the company has more volatile EPS. |
| Degree of Operational Leverage | 18.63 | 94th | Calculated as the ratio of Percentage change in EBIT / Percentage change in revenue. It is a measure of how earnings for the company is impacted by its sales activity. |
Earnings Growth (EBIT)
| Metric | Value | Percentile | What it measures |
|---|---|---|---|
| EBIT Pct Growth | 400.0% | 64th | The EBIT growth rate over the trailing twelve months (TTM) |
| EBIT Pct Growth 3 year CAGR | 48.9% | 46th | The EBIT compound annual growth rate (CAGR) over the past 3 years |
Earnings Growth (EBITDA)
| Metric | Value | Percentile | What it measures |
|---|---|---|---|
| EBITDA Pct Growth | 400.0% | 59th | The EBITDA growth rate over the trailing twelve months (TTM) |
| EBITDA Pct Growth 3 year CAGR | 205.5% | 52nd | The EBITDA compound annual growth rate (CAGR) over the past 3 years |
| EBITDA Pct Growth 5 year CAGR | 209.2% | 95th | The EBITDA compound annual growth rate (CAGR) over the past 5 years |
Profitability
| Metric | Value | Percentile | What it measures |
|---|---|---|---|
| Gross Margin Pct | 92.5% | 96th | Calculated as the ratio of Revenue - Cost of Goods Sold (COGS) / Revenue. The gross margin represents the percent of total sales revenue that the company retains after incurring the direct costs associated with producing the goods and services sold by a company. |
| Operating Margin Pct | 30.0% | 89th | Calculated as the ratio of (Revenue - (Cost of Goods Sold + Labour + Sales, General & Administrative)) / Revenue. Operating margins are important because they measure efficiency. The higher the operating margin, the more profitable a company's core business is. |
| Operating Profit Pct Growth | 400.0% | 98th | The Operating Profit growth rate over the trailing twelve months (TTM) |
| Operating Profit Pct Growth 3 year CAGR (FY) | 48.9% | 92nd | The Operating Profit compound annual growth rate (CAGR) over the past 3 years |
| Operating Profit Pct Growth 5 year CAGR (FY) | 26.4% | 87th | The Operating Profit compound annual growth rate (CAGR) over the past 5 years |
| PreTax Margin Pct | 33.1% | 88th | Calculated as the ratio of (Gross profit - (Operating Expense + Interest Expense)) / Revenue. The pretax profit margin enables profitability to be compared across companies with significant differences in size, scale, capital structure and tax rates. |
| Return on Assets Pct | 21.9% | 97th | Calculated as the ratio of Net Income / Total Assets. It is an indicator of how efficient the company is at using its assets to generate earnings. |
| Return on Equity Pct | 30.8% | 92nd | Calculated as the ratio of Net Income / Shareholders' equity. It is a measure of how much profit a company generates with the money shareholders have invested. |
| Return on Invested Capital Pct | 27.8% | 93rd | Calculated as the ratio of (Net Income - Dividends) / (Debt + Equity). It is a measure of how efficient the company is at allocating the capital under its control to profitable investments. |
Earnings Growth (Net Income)
| Metric | Value | Percentile | What it measures |
|---|---|---|---|
| Net Income Pct Growth | 400.0% | 97th | The Net Income growth rate over the trailing twelve months (TTM) |
| Net Income Pct Growth 3 year CAGR | 64.0% | 95th | The Net Income compound annual growth rate (CAGR) over the past 3 years |
| Net Income Pct Growth 5 year CAGR | 24.5% | 84th | The Net Income compound annual growth rate (CAGR) over the past 5 years |
Cashflow
| Metric | Value | Percentile | What it measures |
|---|---|---|---|
| Operating Cashflow Pct Growth | 296.4% | 95th | The Operating Cashflow growth rate over the trailing twelve months (TTM) |
| Operating Cashflow Pct Growth 3 year CAGR (FY) | 32.7% | 85th | The Operating Cashflow compound annual growth rate (CAGR) over the past 3 years |
| Operating Cashflow Pct Growth 5 year CAGR (FY) | 14.7% | 75th | The Operating Cashflow compound annual growth rate (CAGR) over the past 5 years |
Top Line Growth
| Metric | Value | Percentile | What it measures |
|---|---|---|---|
| Revenue Pct Growth | 21.5% | 77th | The Revenue (Sales) growth rate over the trailing twelve months (TTM) |
| Revenue Pct Growth 3 year CAGR | 15.6% | 77th | The Revenue (Sales) compound annual growth rate (CAGR) over the past 3 years |
| Revenue Pct Growth 5 year CAGR | 14.7% | 73rd | The Revenue (Sales) compound annual growth rate (CAGR) over the past 5 years |
Taxes
| Metric | Value | Percentile | What it measures |
|---|---|---|---|
| Effective Tax Rate Pct | 19.3% | 64th | The effective tax rate of the company over the trailing twelve months (TTM). |
Margins and returns say how much of each dollar of sales becomes profit and how hard the balance sheet is working; leverage and liquidity say how much room the company has when conditions turn. Read the guide: A practical guide to discounted cash flow valuation.
Fair value, peer multiples and the full statement history are in the app: open INCY in FundSpec.
Insider activity
In the last 90 days insiders filed 70 transactions: 7 acquisitions covering 45,077 shares. Acquisitions include awards and option exercises as well as open market purchases. The largest by value was a disposal of 15,888 shares by Pablo J Cagnoni, President, Global Head of R&D on 31 July 2026, worth about $1.9 million at the transaction price.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 1 Oct 2026 | Lee Heeson | EVP, Head of Incyte Intl | F | 463 | $117.14 | $54K |
| 30 Sep 2026 | Edmund Harrigan | Director | Acquisition | 206 | $121.35 | $25K |
| 30 Sep 2026 | Paul J Clancy | Director | Acquisition | 203 | $121.35 | $25K |
| 30 Sep 2026 | Bros. Advisors Lp Baker | Director, 10% Owner | Acquisition | 322 | ||
| 22 Sep 2026 | David H Gardner | EVP, Chief Strategy Officer | F | 920 | $126.93 | $117K |
| 15 Sep 2026 | Pablo J Cagnoni | President, Global Head of R&D | S | 13,985 | $120.49 | $1.7M |
| 15 Sep 2026 | Pablo J Cagnoni | President, Global Head of R&D | S | 9,233 | $120.50 | $1.1M |
| 15 Sep 2026 | Pablo J Cagnoni | President, Global Head of R&D | M | 9,233 | $71.93 | $664K |
| 15 Sep 2026 | Pablo J Cagnoni | President, Global Head of R&D | M | 6,477 | $64.25 | $416K |
| 15 Sep 2026 | Pablo J Cagnoni | President, Global Head of R&D | M | 4,551 | $61.18 | $278K |
| 15 Sep 2026 | Pablo J Cagnoni | President, Global Head of R&D | M | 2,957 | $61.76 | $183K |
| 15 Sep 2026 | Pablo J Cagnoni | President, Global Head of R&D | M | 2,957 | ||
| 15 Sep 2026 | Pablo J Cagnoni | President, Global Head of R&D | M | 4,551 | ||
| 15 Sep 2026 | Pablo J Cagnoni | President, Global Head of R&D | M | 6,477 | ||
| 15 Sep 2026 | Pablo J Cagnoni | President, Global Head of R&D | M | 9,233 |
Insider filings record what officers and directors did with their own shares. Disposals are often planned sales or tax related, so a pattern across several insiders says more than one filing.
SEC filings
The latest filing is a 10-Q from 28 July 2026.
| Filed | Form | Document |
|---|---|---|
| 28 Jul 2026 | 10-Q | View on sec.gov |
| 28 Apr 2026 | 10-Q | View on sec.gov |
| 10 Feb 2026 | 10-K | View on sec.gov |
| 28 Oct 2025 | 10-Q | View on sec.gov |
| 29 Jul 2025 | 10-Q | View on sec.gov |
| 29 Apr 2025 | 10-Q | View on sec.gov |
| 10 Feb 2025 | 10-K | View on sec.gov |
| 29 Oct 2024 | 10-Q | View on sec.gov |
| 30 Jul 2024 | 10-Q | View on sec.gov |
| 30 Apr 2024 | 10-Q | View on sec.gov |
Company profile
- Exchange
- Nasdaq
- Sector
- Engineering, Accounting, Research, Management
- Industry
- Business Services
- Headquarters
- Wilmington, Delaware
- Chief executive
- Herve Hoppenot
- Employees
- 2,320
- Website
- incyte.com
- SEC CIK
- 0000879169
Incyte Corporation focuses on the discovery, development, and commercialization of proprietary therapeutics. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD) It also develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Sector and peers
Incyte Corp. is part of the Engineering, Accounting, Research, Management sector, which FundSpec tracks across 43 companies.
Companies in the same industry by market capitalization:
IQV IQVIA Holdings Inc.CRL Charles River Laboratories International, Inc.
Put two of them side by side in Compare.
In FundSpec: the fair value estimate, the momentum reading, relative valuation against sector and industry peers, unusual options activity and AI model signals for INCY are available to subscribers, with the same screen in the iOS and Android apps.
Open INCY in FundSpec